EuResist Network GEIE
Via Guido Guinizelli, 98/100 - 00152 Rome - Italy
Tel. +39 06 5758926 - Fax +39 06 62207168

VAT N. 09950311002 / reg. N° RM-1199300


CEO: Dr. Francesca Incardona

e-mail: f.incardona@euresist.org

EuResist Network GEIE
© 2017 All Right Reserved

The overall objective of CARE Common Action aganist HIV/TB/HCV Acoss the Region of Europe is to analyse and combat the human immunodeficiency virus (HIV), tuberculosis (TB) and hepatitis C (HCV) epidemics across the European Region with a specific focus on the Russian Federation, through the establishment and expansion of previously created EU-Russian networks. The consortium consists of cutting edge scientists from across Europe including Russia able to collectively address ongoing public health challenges related to HIV, TB and HCV.

The short-term objective of the project within the 2-year framework is to generate novel research findings based on existing biological material and data already collected by the consortium partners as well as on new samples and data gathering.

CARE on the news:

Il Sole 24 ore 24 Jan 2019

The specific objectives of CARE are to:

  • Discover and validate novel soluble biomarkers reliably able to identify treatment success of multidrug resistant tuberculosis (MDR-TB) patients and to diagnose pulmonary tuberculosis.

  • Explore mechanisms explaining susceptibility to develop extrapulmonary tuberculosis related to variants of the host gene SIGLEC1 that are also involved in response to HIV infection.

  • Analyse the correlation between drug-related variants in the tuberculosis genome and corresponding in vitro drug susceptibility to develop a decision making support tool for the choice of second line therapy in case of suspected MDR-TB.

  • Define epidemiology and pathways of drug-resistant HIV, including their relationship with HIV subtypes and TB coinfection, across the European Region including Russia, in order to better inform health policies and clinicians for an evidence-based introduction of integrase strand transfers inhibitors (INSTI) as part of first line antiretroviral therapy.

  • Discover and validate variants in the host genome influencing susceptibility to contracting AIDS and serious non-AIDS clinical events and adverse reactions to antiretroviral medicines in HIV-mono-infected and TB and/or HCV-coinfected patients.

  • Compile experience for treating HCV infection by use of direct-acting antivirals from across Europe in order to inform best practice recommendations for how to use such medication in settings with current limited access and limited budgets.

 

The longer-term objective of the CARE project is to implement the necessary collaborative research infrastructure allowing the expansion of activities beyond the funding frame, sustaining the partners to share technology, protocols, structured data collections and knowledge to fuel and maintain cooperation and foster future research plans beyond the duration of CARE.

Participants

1. EuResist Network (coordinator) 

Italy

2. REGIONH 

Denmark

3. Karolinska Institutet 

Sweden

4. University of Siena 

Italy

5. Eberhard Karls Universitaet Tuebingen 

Germany

6. Forschungszentrum Borstel 

Germany

7. Institutia Medico-sanitaria Publica - Institutul de ftiziopneumologie "CHIRIL DRAGANIUC" 

8. Imperial College of Science Technology and Medicine 

UK

9. Viesoji Staiga Vilniaus Universiteto Ligonine Santaros Klinikos (VULSK)

Lithuania

10. Public Health Center of the Ministry of Health of Ukraine 

Ukraine

11. Infectious Diseases, AIDS and Clinical Immunology Research Center 

Georgia

12. Federal research centre for epidemiology and microbiology named after the honorary academician N.F. Gamaleya of the Ministry of health of Russia 

Russian Federation

This project has received funding from the European Union’s Horizon 2020 research and innovation
programme under grant agreement No 825673